Document is current
Any future updates will be listed below
-
Authors
Selenica, Pier
Dopeso, Higinio
Repetto, Matteo
Basili, Thais
Gazzo, Andrea M.
Schwartz, Christopher J.
Derakhshan, Fatemeh
Marra, Antonio
Ferrando, Lorenzo
Beets-Tan, Regina G. H.
Wen, Y. H.
Ross, Dara S.
Brogi, Edi
Zhang, Hong
Norton, Larry
Chandarlapaty, Sarat
Razavi, Pedram
Mandelker, Diana
Reis-Fiho, Jorge S.
Weigelt, Britta
Pareja, Fresia
-
Funding
Funding for this research was provided by:
European Society For Medical Oncology (ESMO) José Baselga Fellowship for Clinician Scientists sponsored by AstraZeneca.
Breast Cancer Research Foundation
MSK SPORE on Genomic Instability in Breast Cancer NIH/NCI (P50CA247749 01, P50CA247749 01, P50CA247749 01)
Cancer Center Support Grant of the NIH/NCI (P30CA008748)
U.S. Food and Drug Administration (1U01FD007909-01A1)
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 13 June 2025
First Online: 10 July 2025
Competing interests
: A.M. reported consulting or advisory role for Menarini/Stemline and AstraZeneca, honoraria as speaker’s bureau from Roche and Eli Lilly, received travel accommodation from Menarini/Stemline and Daiichi Sankyo, outside the submitted work. S.C. has received institutional grant/funding from Daiichi-Sankyo, AstraZeneca, and Lilly, Share options Totus Medicines, and consultation/Ad board/Honoraria from AstraZeneca, Lilly, Casdin Capital, Nuvalent, Blueprint, and SAGA Diagnostics. J.S.R.-F. is an employee of AstraZeneca and owns AstraZeneca stocks. Prior Conflicts of Interest in the last 2 yeas include the receipt of personal fees for the following activities: Board Membership at Grupo Oncoclinicas, consultant for Goldman Sachs Merchant Banking, consultant for Bain Capital, consultant for and SAB member of Paige.ai, consultant for and SAB member of Repare Therapeutics, Consultant of SAGA Diagnostics, Consultant of Personalis, and consultant at MultiplexDx. B.W. reports research grants from REPARE Therapeutics and SAGA Diagnostics paid to the institution, and employment of an immediate family member at AstraZeneca. F.P. reports membership on advisory boards for AstraZeneca and MultiplexDx, as well as receipt of consultancy fees from AstraZeneca. All other authors have nothing to disclose.
